New PDCoV strain linked to 2024 piglet outbreak in central China

A severe diarrheal outbreak on a pig farm in central China has yielded a newly characterized porcine deltacoronavirus strain that may test the relevance of older vaccine references. In a Frontiers in Veterinary Science report, researchers said the outbreak occurred in December 2024 on a Hubei farm with about 2,100 sows, affecting neonatal piglets with acute watery diarrhea, dehydration, and lethargy. Mortality among affected piglets was about 20%, or an estimated 240 deaths. (frontiersin.org)

The isolate, designated SP2403-2, was recovered from intestinal contents of a diseased piglet and identified as the primary etiologic agent after testing ruled out PEDV, TGEV, porcine rotavirus, Getah virus, and PCV2 in the sampled animal. That’s notable because PDCoV often enters the differential alongside other enteric pathogens, and the literature shows coinfections with PEDV and others are common in field cases. On this farm, sows had been vaccinated during gestation against PEDV and TGEV, but no PDCoV-specific vaccine had been used before the outbreak. (frontiersin.org)

PDCoV isn’t new, but it remains a consequential enteric pathogen in swine. The virus was first identified in Hong Kong in 2012 and later spread across multiple countries, including the United States. Reviews and meta-analyses suggest PDCoV has remained widely distributed in Chinese pig populations, with central China reporting comparatively high prevalence in published surveillance studies. (frontiersin.org)

What makes this report stand out is the spike protein analysis. The near-complete SP2403-2 genome measured 25,244 nucleotides and shared its highest similarity, 99.2%, with a recent Chinese strain called JSTZ2025, while phylogenetic analysis placed it firmly within the Chinese lineage. Compared with the Chinese vaccine strain CHN-HN-2014, the new isolate carried 25 amino acid substitutions in the spike protein. The authors mapped many of those changes to surface-exposed regions, especially in the S1 N-terminal domain, an area tied to neutralizing antibody induction. (frontiersin.org)

That concern is biologically plausible based on outside research. A 2024 Nature Communications study showed that PDCoV neutralizing antibody binding can be highly sensitive to relatively small changes in the spike protein, and that variation near key epitopes may reflect immune pressure in the field. In other words, the Frontiers paper does not prove vaccine escape, but it does strengthen the case that antigenic drift deserves closer attention. (nature.com)

There’s also a broader pattern emerging. Another 2026 report from China described a separate 2024 PDCoV diarrhea outbreak in Guangxi and found a Chinese-lineage strain with spike changes associated with altered surface conformation and strong pathogenicity in newborn piglets. Taken together, these studies suggest that contemporary Chinese PDCoV strains are not static, and that recent field isolates are becoming more important reference points for both surveillance and product development. (pubmed.ncbi.nlm.nih.gov)

Why it matters: For veterinarians and swine health teams, this is a reminder that “known” enteric coronaviruses can still shift in ways that matter operationally. If spike variation accumulates in antigenically important regions, older vaccine strains, assay targets, and herd-level expectations may become less reliable over time. The immediate clinical takeaway isn’t that current tools have failed across the board, but that diagnostic confirmation, sequencing, and regional surveillance are becoming more valuable when outbreaks don’t behave as expected. For mixed-enteric disease investigations, PDCoV still belongs high on the list, even where PEDV and TGEV vaccination programs are already in place. (frontiersin.org)

What to watch: The next key step is functional evidence. The Hubei paper calls for cross-neutralization and vaccine efficacy work, and that’s what the field will need to judge whether these spike changes translate into meaningful loss of protection. Also worth watching are additional GenBank deposits, more reports from central and southern China, and whether commercial or experimental vaccine programs begin shifting toward newer Chinese-lineage isolates as seed strains. (frontiersin.org)